Biotech Stocks Rally After Hours on FDA Designations and Clinical Trial Progress
核心洞察
Stoke Therapeutics surged 11.42% after presenting positive data for zorevunersen in Dravet syndrome (搜索) at the 2025 AES Annual Meeting with partner Biogen.
Alpha Tau Medical climbed 25.26% following announcement that the first patient was treated in its pilot study for recurrent glioblastoma multiforme (搜索) using Alpha DaRT technology.
Senti Biosciences gained 3.92% after the FDA granted RMAT designation to SENTI-202, an investigational CAR-NK cell therapy for acute myeloid leukemia (搜索) and other hematologic malignancies.
Biotech stocks demonstrated significant after-hours momentum on Monday, with several companies posting double-digit gains following clinical data presentations, FDA regulatory designations, and trial progress announcements. The sector rally highlighted key catalysts that investors are closely monitoring across oncology, neurology, and rare disease therapeutic areas.
Clinical Data Drives Stoke Therapeutics Rally
Stoke Therapeutics led the after-hours gainers, surging 11.42% to $33.95 after closing down 7.67% at $30.47 during regular trading. The rebound followed data presentations with partner Biogen at the 2025 AES Annual Meeting, supporting the potential of zorevunersen for treating Dravet syndrome (搜索), a rare and severe form of epilepsy.
Alpha Tau Medical Advances Glioblastoma Treatment
Alpha Tau Medical experienced the largest percentage gain, climbing 25.26% to $5.30 in after-hours trading. The company announced that the first patient has been treated in its pilot study for patients with recurrent glioblastoma multiforme (搜索) using the Alpha DaRT technology. The stock had already gained 8.74% during regular trading hours, closing at $4.23.
FDA Grants RMAT Designation to Senti Biosciences
Senti Biosciences rallied 3.92% to $1.60 after hours, recovering from a steep 35.56% decline during regular trading to $1.54. The company received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202, its investigational CAR-NK cell therapy targeting acute myeloid leukemia (搜索) and other hematologic malignancies. The RMAT designation is designed to expedite the development and review of regenerative medicine therapies that address unmet medical needs.
Additional Clinical Progress and Corporate Developments
Absci Corp rose 3.69% to $3.65 after hours, building on a 2.03% gain to close at $3.52. While no fresh news emerged on Tuesday, the company had announced on December 4 the first volunteer dosing in its Phase 1/2a HEADLINE study of ABS-201, an investigational anti-PRLR (搜索) antibody.
COMPASS Pathways climbed 4.40% to $6.64 after finishing regular trading at $6.36. The company announced plans to host a webinar on January 7, 2026, covering commercial preparations for treatment-resistant depression (搜索) and clinical trial plans for post-traumatic stress disorder (搜索).
Financing and Strategic Developments
TuHURA Biosciences edged up 0.85% to $1.18 after hours, following a significant 40.91% decline to $1.17 at the close. The company announced a registered direct offering of 9.4 million shares and warrants, priced at $1.65 per share.
Maravai LifeSciences Holdings advanced 7.32% to $3.86 after hours, following a 2.22% gain to close at $3.69, despite no company-specific news being reported.
The after-hours rally across multiple biotech names reflects investor appetite for companies demonstrating clinical progress and regulatory advancement, particularly in areas with significant unmet medical needs such as rare neurological disorders, aggressive brain cancers, and hematologic malignancies.